Published in Clin Exp Immunol on October 01, 2009
Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol (2011) 1.11
Signaling through FcRγ-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses. J Allergy Clin Immunol (2014) 0.87
Recommendation for optimal management of severe refractory asthma. J Asthma Allergy (2010) 0.81
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81
Antagonism of cytokine-induced eosinophil accumulation in asthma. Front Pharmacol (2012) 0.77
Mega-dose vitamin C attenuated lung inflammation in mouse asthma model. Anat Cell Biol (2010) 0.77
Unusual asthma syndromes and their management. Ther Adv Chronic Dis (2011) 0.75
Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response. J Allergy Clin Immunol (2015) 0.75
Methyl methacrylate and respiratory sensitization: a critical review. Crit Rev Toxicol (2011) 0.75
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 10.76
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (2002) 8.57
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med (2000) 8.09
Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med (2002) 6.52
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med (2009) 5.90
Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med (2008) 5.80
The global burden of asthma. Chest (2006) 5.74
A critical role for eosinophils in allergic airways remodeling. Science (2004) 5.53
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med (2006) 4.83
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med (2002) 4.67
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet (2007) 3.90
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med (2007) 3.83
Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med (2003) 3.34
The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol (2003) 3.22
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest (2003) 3.16
Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 3.11
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J (2006) 3.09
Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol (1994) 2.73
Retracted The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med (2006) 2.72
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol (2009) 2.54
Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev (2006) 2.47
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med (2003) 2.45
Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol (2007) 2.43
Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol (1997) 2.28
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 2.19
IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol (2002) 2.01
Development and function of TH17 cells in health and disease. J Allergy Clin Immunol (2009) 1.95
The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax (2008) 1.93
TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol (2002) 1.92
Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol (2008) 1.92
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol (2007) 1.80
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol (1995) 1.76
Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol (2008) 1.76
T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol (2008) 1.76
Severe asthma in adults. Am J Respir Crit Care Med (2005) 1.74
Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol (2007) 1.71
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.70
Bronchial inflammation and airway responses to deep inspiration in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.68
Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med (1999) 1.62
New insights into the role of the mast cell in asthma. Clin Exp Allergy (2003) 1.61
Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy (2003) 1.61
Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol (2005) 1.52
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 1.52
Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med (2001) 1.49
New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) (2002) 1.47
Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J (2002) 1.45
Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J (2003) 1.44
Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med (1997) 1.39
Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy (2003) 1.37
Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol (2006) 1.35
IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol (2003) 1.35
Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1. J Immunol (2008) 1.34
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol (2001) 1.32
Eosinophils in asthma and other allergic diseases. Br Med Bull (2000) 1.32
TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy (1991) 1.17
Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest (1991) 1.16
Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax (2009) 1.14
Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur Respir J (2007) 1.11
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol (2002) 1.07
Is the neutrophil the key effector cell in severe asthma? Thorax (2005) 1.06
The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol (1995) 1.00
The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy (2005) 0.97
Granulocyte-macrophage colony-stimulating factor is required for bronchial eosinophilia in a murine model of allergic airway inflammation. J Immunol (2008) 0.91
Novel targets of therapy in asthma. Curr Opin Pulm Med (2009) 0.91
Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. Respiration (2005) 0.85
Asthma treatment: 'magic bullets which seek their own targets'. Allergy (2007) 0.83
Azithromycin therapy for neutrophilic airways disease: myth or magic? Thorax (2009) 0.82
Eosinophils in asthma and other allergic diseases. Br Med Bull (2000) 1.32
Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J (2005) 0.99
Airway wall geometry in asthma and nonasthmatic eosinophilic bronchitis. Allergy (2009) 0.88
Airway smooth muscle proliferation and survival is not modulated by mast cells. Clin Exp Allergy (2009) 0.87
The airway smooth muscle CCR3/CCL11 axis is inhibited by mast cells. Allergy (2008) 0.85
Airway smooth muscle chemokine receptor expression and function in asthma. Clin Exp Allergy (2009) 0.80